Trial Search Results

Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Procedure: Hypo-fractionated Radiotherapy


Phase 2


Inclusion Criteria:- Eligible patients will have clinical stage T1c through T2b, initial
PSA level <10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores

   - Patients who have had any form of prior curative treatment (surgery, radiotherapy,
   cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3
   months duration will be allowed.

   - Adult men will be considered.

   - No life expectancy restrictions will apply.

   - Performance Status will not be considered.

   - No requirements for organ or marrow function will be made

   - Ability to understand and the willingness to sign a written informed consent document.
   Exclusion Criteria:- No prior prostate treatment will be allowed.

   - The use of other concurrent Investigational Agents will not be allowed.

   - No exclusion requirements due to co-morbid disease or incurrent illness.

   - No requirements regarding history of allergic reactions.

   - Pregnancy or nursing patients is not applicable (ie. patients are male).

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Gillian McFarlane